Project Data Sphere, an independent not-for-profit initiative, has launched a data sharing platform
Project Data Sphere (PDS), an independent not-for-profit initiative has launched a data sharing platform that has been specifically designed to provide one place where the cancer community can broadly share, integrate and analyze historical patient level, comparator arm data from academic and industry phase III cancer clinical trials. The initiative addressed prior obstacles to clinical trial data sharing by working with leading legal and privacy experts, as well as clinicians, commercial institutions and patient representatives to build an optimal framework to share data responsibly.
Initial data sets of de-identified, patient level data, have been provided by AstraZeneca, Bayer, Celgene, Janssen Research and Development, an affiliate of Johnson & Johnson, Memorial Sloan Kettering Cancer Center, Pfizer, and Sanofi US. PDS is currently working with these and other organizations, including the Alliance for Clinical Trials in Oncology (sponsored by the National Cancer Institute), Amgen, and Quintiles to provide additional cancer data sets.
The Project Data Sphere platform was developed by SAS, an industry leader in data security and analytics. State of the art analytic tools are available on demand to registered users within the platform.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.